A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer's Disease ("Protocol").

Grant number: 5R01AG053267 WU-19-308 | Funding period: 2018 - 2021

Active

Researchers